flutamide has been researched along with leuprolide in 194 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (4.12) | 18.7374 |
| 1990's | 91 (46.91) | 18.2507 |
| 2000's | 66 (34.02) | 29.6817 |
| 2010's | 29 (14.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Hattab, B; Kaskas, M; Sauvage, L | 1 |
| Huben, RP | 1 |
| Blumenstein, BA; Crawford, ED; Dorr, FA; Eisenberger, MA; McLeod, DG | 1 |
| Cusan, L; Dupont, A; Emond, J; Gomez, JL; Labrie, F; Lacourcière, Y; Monfette, G; Tremblay, M | 1 |
| Amrani Akdi, Y; Leva Vallejo, M; Molina Sánchez, J; Prieto Castro, R; Regueiro López, JC; Requena Tapia, MJ; Saceda López, JL | 1 |
| Baum, N; Brown, P | 1 |
| Dawson, NA; Frank, JA; Gelmann, EP; Jacob, JL; Linehan, WM; McLeod, DG; Weiss, RB; Wilding, G | 1 |
| Chime-Udeh, E | 1 |
| Imai, K; Nakata, S; Nakazawa, Y; Takahashi, O; Watanabe, K; Yamanaka, H | 1 |
| Denis, L | 1 |
| Crawford, ED; Nabors, WL | 1 |
| Barrows, GH; Murphy, WM; Soloway, MS | 1 |
| Crawford, ED; Nabors, W | 1 |
| Chodoff, L | 1 |
| Benson, R; Blumenstein, BA; Crawford, ED; Davis, MA; Dorr, FA; Eisenberger, MA; Goodman, PJ; McLeod, DG; Spaulding, JT | 2 |
| Blumenstein, B; Crawford, ED; Goodman, P | 1 |
| Allen, JA; Crawford, ED | 1 |
| Crawford, ED | 2 |
| Bruchovsky, N; Fletcher, T; Foekens, JA; Goldenberg, SL; Lawson, D; Rennie, PS | 1 |
| Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y; Monfette, G | 1 |
| Lynch, JH; O'Brien, WM | 1 |
| Kung, TT; Mingo, GG; Siegel, MI; Watnick, AS | 1 |
| Soloway, MS | 2 |
| Crawford, ED; DeAntoni, E | 1 |
| Kane, CJ; Keizur, JJ; Leidich, RB; North, R | 1 |
| Faerber, GJ; Rozanski, TA | 1 |
| Andros, EA; Crawford, ED; Danesghari, F | 1 |
| Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N | 2 |
| McLeod, D; Puras-Baez, A; Sharifi, R; Soloway, MS; Wajsman, Z; Wood, DP | 1 |
| Barnes, MM; Broderick, GA; Dougherty, MJ; Malkowicz, B; Van Arsdalen, K; Wein, AJ; Whittington, R | 1 |
| Candas, B; Cusan, L; Diamond, P; Fradet, Y; Gomez, JL; Labrie, F; Lemay, M; Suburu, R; Têtu, B | 1 |
| Abi-Aad, A; Belldegrun, A; Danella, J; deKernion, JB; Macfarlane, MT; Stein, A | 1 |
| Braslis, KG; Civantos, F; Davi, RC; Nelson, E; Soloway, MS | 1 |
| Carroll, PR; Lowe, BA; Narayan, P; Thompson, IM | 1 |
| Cusan, L; Diamond, P; Dupont, A; Fradet, Y; Gomez, J; Koutsilieris, M; Labrie, F; Lemay, M; Suburu, R; Têtu, B | 1 |
| Dorr, RP; Lee, F; McHugh, TA; Siders, DB; Solomon, MH | 1 |
| Burman, CM; Fuks, Z; Happersett, L; Harrison, A; Kutcher, GJ; Leibel, SA; Zelefsky, MJ | 1 |
| Bergstrahl, E; Bostwick, DG; Ellison, E; Ferguson, J; Zincke, H | 1 |
| Bergan, RC; Cooper, MR; Figg, WD; Headlee, D; Humphrey, J; Reed, E; Sartor, O; Thibault, A | 1 |
| Murphy, WM; Smith, DM | 1 |
| DeAngelis, LM; Mencel, PJ; Motzer, RJ | 1 |
| Carrascosa, M; Cillero, L; Mendez, MA; Perez-Castrillon, JL; Valle, R | 1 |
| Benson, RC; Blumenstein, BA; Crawford, ED; Eisenberger, MA; McLeod, DG; Spaulding, JT; Spicer, D | 1 |
| Benson, RC | 1 |
| Bélanger, A; Dupont, A; Labrie, F; Luu-The, V; Simard, J | 1 |
| Akaza, H; Imada, S; Koiso, K; Otani, M | 1 |
| Gormley, EA; Schned, AR | 1 |
| Alvarez Kindelan, J; Leva Vallejo, M; Merchan García, JA; Prieto Castro, R; Regueiro López, JC; Requena Tapia, MJ; Ruiz Alvarez Cienfuegos, F | 1 |
| Corn, BW; Gomella, LG; Hyslop, T; Liberman, SN; Mulholland, SG; Petersen, RO | 1 |
| Civantos, F; Pinto, JE; Soloway, MS | 1 |
| Acar, O; Goldschmidt, AJ; Tunn, UW | 1 |
| Baisi, B; Castagnetti, G; Dotti, A; Ferrari, G; Ferrari, P | 1 |
| Banks, ER; Civantos, F; Drew, PA; Ho, CK; Marcial, MA; Murphy, WM; Soloway, MS; Speights, VO | 1 |
| Têtu, B | 1 |
| Ellis, W; Higano, CS; Lange, PH; Russell, K | 1 |
| Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Barbara, L; Cicognani, C; Malavolti, M; Morselli-Labate, AM; Sama, C | 1 |
| di Salle, E; Giudici, D; Zaccheo, T | 1 |
| Candas, B; Cusan, L; Diamond, P; Fortin, A; Gomez, JL; Labrie, F; Laverdière, J; Lemay, M; Suburu, ER | 1 |
| Patel, H; Rhee, E; Zimmern, PE | 1 |
| Harrison, A; Zelefsky, MJ | 1 |
| Coffield, S; Johnson, CF; Klein, E; McLeod, DG; Peabody, JO; Soloway, M | 1 |
| Akaza, H; Ami, Y; Ideyama, Y; Imada, S; Koiso, K; Takenaka, T | 1 |
| Duray, P; Figg, WD; Kroog, G; Patronas, N; Reed, E; Sartor, O; Walther, MM | 1 |
| Akaza, H; Aso, Y; Isaka, S; Kanetake, H; Koiso, K; Kotake, T; Usami, M | 1 |
| Ghusn, H; Kunik, ME; Orengo, CA; Yudofsky, SC | 1 |
| Caprano, J; Enzmann, T; Köllermann, J; Köllermann, MW; Pantel, K; Riethmüller, G | 1 |
| Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Myers, CE; Reed, E; Sartor, O; Sausville, EA; Senderowicz, AM; Steinberg, SM; Tompkins, A; Weinberger, B | 1 |
| Cano, T; Fernández-Juarez, G; Marcén, R; Ortuño, J; Rivera, M; Teruel, JL; Villafruela, JJ | 1 |
| Colecchia, M; Colloi, D; Del Boca, C; Frigo, B; Guardamagna, A; Leopardi, O; Zucchi, A | 1 |
| Harbour, D; Liebmann, J; Smith, A | 1 |
| Acerno, S; Giovanelli, M; Giugni, E; Grasso, M; Losa, M; Mortini, P | 1 |
| Block, NL; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Anderson, PR; Hanks, GE; Hanlon, AL; Movsas, B | 1 |
| Gordon, RE; Stock, R; Stone, N; Unger, PD; Wang, Q | 1 |
| Jennings, TA; Nazeer, T; Ross, JS; Tran, TA | 1 |
| Abe, F; Kuroiwa, S; Okada, M; Tomura, A | 1 |
| Benvenuti, C; Bono, AV; Brausi, M; DiSilverio, F; Ferrari, P; Galli, L; Gibba, A; Robustelli della Cuna, G | 1 |
| Corn, BW; Gomella, L; Hyslop, T; Mulholland, SG; Valicenti, RK | 1 |
| Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z | 1 |
| Block, NL; Chodak, GW; Klein, EA; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Renfer, LG; Rozanski, TA; Schow, DA; Thompson, IM | 1 |
| Hirao, Y; Ozono, S | 1 |
| Burman, C; Fuks, Z; Leibel, SA; Ling, CC; Lyass, O; Wolfe, T; Zelefsky, MJ | 1 |
| Costabile, RA | 1 |
| Wajsman, Z | 1 |
| Azuma, T; Kurimoto, S; Mikami, K; Oshi, M | 1 |
| Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Akazawa, S; Aki, M; Hashine, K; Kuwahara, M; Sumiyoshi, Y; Takenaka, A; Yamamoto, A | 1 |
| Balaji, KC; Bastar, A; Fair, WR; Rabbani, F; Tsai, H | 1 |
| Chang, CP; Sun, CF; Tsao, KC; Wu, JT; Wu, TL | 1 |
| Labrie, F; Tetu, B; van der Kwast, TH | 1 |
| Carroll, K; Johnson, R; Kolvenbag, GJ; Sarosdy, MF; Schellhammer, PF | 1 |
| Baba, S; Egawa, S; Kuwao, S; Matsumoto, K; Mizoguchi, H; Takashima, R | 1 |
| Herr, HW; O'Sullivan, M | 1 |
| Aizawa, Y; Ikemoto, I; Ohishi, Y; Wada, T; Yamazaki, H | 1 |
| Behar, RJ; Cantor, A; Chovnick, SD; Donohue, M; Huff, W; Otheguy, J; Perez, R; Rabinowitz, R; Sharkey, J; Solc, Z; Steele, J; Webster, C | 1 |
| Bruchovsky, N; Gleave, ME; Goldenberg, SL; Jones, EC; La Bianca, SE; Sullivan, LD | 1 |
| Granter, SR; Renshaw, AA | 1 |
| Abe, H; Ito, H; Miura, T; Nishimura, T; Oaki, Y; Oka, F; Uchikoba, T | 1 |
| Stock, RG; Stone, NN; Unger, P | 1 |
| Gleave, M; Goldenberg, SL; Klotz, L | 1 |
| Feek, U; Helpap, B; Kaulfuss, U; Köllermann, J; Köllermann, MW; Müller, H; Oehler, U | 1 |
| Fukabori, Y; Ito, K; Kurokawa, K; Nakazato, H; Suzuki, K; Yamanaka, H | 1 |
| Leibowitz, RL; Tucker, SJ | 1 |
| Kumon, H; Maki, Y; Nasu, Y; Noda, M; Saika, T; Suyama, B; Tsushima, T; Yamato, T | 1 |
| Almeida, OP; Flicker, L; Fonte, J; Gandy, S; Lim, D; Martins, RN; Spry, N; Waterrus, A | 1 |
| Arango Toro, O; Bielsa Gali, O; Gelabert Mas, A; Griño Garreta, J; Lorente Garín, JA | 1 |
| Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ | 1 |
| Chetner, M; Chin, JL; Dupont, C; Gleave, ME; Goldenberg, SL; Jewett, M; Kassabian, V; Klotz, LH; Saad, F; Van Rensselaer, S; Warner, J | 1 |
| Aguilar-Cordova, E; Ayala, G; Brady, J; Butler, EB; Caillouet, J; Carpenter, LS; Chiu, JK; Chou, CC; Davis, M; Kadmon, D; Kernen, K; Lu, HH; Mai, WY; Miles, B; Shalev, M; Teh, BS; Thompson, T; Vlachaki, MT; Wheeler, T; Woo, SY | 1 |
| Fukuoka, H; Harada, M; Hosaka, M; Kitami, K; Miura, T; Moriyama, M; Noguchi, K; Uemura, H | 1 |
| McLeod, D; Pareek, K; Puras-Baez, A; Sharifi, R; Soloway, MS; Wajsman, Z; Wood, DP | 1 |
| Gu, F; Guo, Y; Hao, J; Kong, X; Mi, P; Na, Y; Pan, B; Wang, J; Xia, T; Xue, Z; Zeng, L | 1 |
| Angeli, A; Ardissone, P; Berruti, A; Cerutti, S; De Luca, S; Dogliotti, L; Fasolis, G; Fontana, D; Isaia, G; Mari, M; Reimondo, G; Rossetti, SR; Tarabuzzi, R; Terrone, C | 1 |
| Candas, B; Cusan, L; Gomez, JL; Labrie, F | 1 |
| Kiriyama, I; Nishimura, T; Ogaki, K; Ohba, S | 1 |
| Mizokami, A; Namiki, M | 1 |
| Duncan, WE; Harding, P; Howard, RS; McLeod, DG; Preston, DM; Torréns, JI | 1 |
| Agarwal, S; Bulpitt, CJ; Dockery, F; Rajkumar, C | 1 |
| Foppiano, F; Franzone, P; Marcenaro, M; Sanguineti, G; Vitale, V | 1 |
| Adachi, H; Doyu, M; Inukai, A; Katsuno, M; Kobayashi, Y; Minamiyama, M; Sang, C; Sobue, G | 1 |
| Cherrier, MM; Higano, C; Rose, AL | 1 |
| Einhorn, LH; Foster, RS; Henley, JD; Sheski, FD | 1 |
| Budde, A; Caprano, J; Helpap, B; Hopfenmüller, W; Köllermann, J; Weidenfeld, H; Weidenfeld, M | 1 |
| Grigoriadis, N; Kallinikidis, T; Kalpidis, P; Karakolios, A; Kasapis, C | 1 |
| Brooks, JD; Chao, DH; Higgins, JP | 1 |
| Aguilar, L; Aguilar-Cordova, E; Ayala, G; Butler, EB; Caillouet, J; Carpenter, LS; Chiu, JK; Davis, M; Kadmon, D; Lu, HH; Mai, WY; Miles, B; Teh, BS; Thompson, T; Timme, TL; Vlachaki, MT; Wheeler, T; Woo, SY | 1 |
| Stock, RG; Stone, NN | 1 |
| Almeida, OP; Flicker, L; Martins, RN; Spry, N; Waterreus, A | 1 |
| Gardiner, RA; Green, HJ; Headley, BC; Mactaggart, P; Nicol, DL; Pakenham, KI; Swanson, C; Watson, R; Yaxley, J | 1 |
| Benaim, EA; Karam, JA; Lin, V; McConnell, JD; Roehrborn, CG; Soboorian, MH | 1 |
| Akakura, K; Isaka, S; Ito, H; Masai, M; Nakatsu, H; Sato, N; Tanaka, M | 1 |
| D'Amico, AV; DellaCroce, A; Kantoff, PW; Loffredo, M; Manola, J; Renshaw, AA | 1 |
| Adachi, H; Katsuno, M; Sobue, G | 1 |
| Brown, J; Higano, C; Shields, A; Tangen, C; Wood, N | 1 |
| Gratzle, J; Jani, AB; Myers, M | 1 |
| Bern, MM | 1 |
| Gratzle, J; Jani, AB | 1 |
| Avances, C; Lucas, C; Maubach, L; Mottet, N; Sene, E; Wolff, JM | 1 |
| Corica, T; Gurney, H; Hayden, L; Hooton, B; Korbel, E; Kristjanson, L; McCaul, K; Neerhut, G; Spry, NA; Weinstein, S | 1 |
| Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I | 1 |
| Azumi, M; Hashimoto, H; Kakizaki, H; Saga, Y | 1 |
| Benson, MC; Brody, R; Ennis, RD; Heymann, JJ; Malyszko, B; Mansukhani, MM; O'Toole, KM; Schiff, PB; Vecchio, D | 1 |
| Ballman, KV; Bodner, BK; Cosar, EF; Kwon, ED; Manecke, RG; Mercader, M; Moser, MT; Sengupta, S; Wojcik, EM | 1 |
| Agarwal, A; Pahalajani, G; Raina, R; Zippe, C | 1 |
| Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I | 1 |
| Matthews, PA | 1 |
| Hashimoto, Y; Ikarashi, T; Nishiyama, T; Takahashi, K; Wako, K | 1 |
| Chen, HH; Cheng, YC; Hsieh, RK; Lim, KH; Lin, CJ; Wu, CJ | 1 |
| Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, B; Renshaw, AA | 1 |
| Kempkensteffen, C; Kleinschmidt, K; Köllermann, J; Pantel, K; Rau, T; Schostak, M; Weikert, S | 1 |
| Brower, V | 1 |
| Davidson, A; Davies, R; Galvão, DA; Joseph, D; La Bianca, S; Prince, R; Spry, NA | 1 |
| Burri, RJ; Cesaretti, JA; Ho, AY; Stock, RG; Stone, NN | 1 |
| Delvoye, N; Gannon, PO; Lapointe, R; Mes-Masson, AM; Poisson, AO; Saad, F | 1 |
| O'Rourke, ME; Ruble, K | 1 |
| Etzioni, RD; Gulati, R; Higano, CS; Jiang, P; Nelson, PS; Russell, KJ; Tam, S; Telesca, D; Yu, EY | 1 |
| Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A | 1 |
| Ahlgren, G; Angelsen, A; Solberg, A; Tasdemir, I; Widmark, A | 1 |
| Kobayashi, M; Kurokawa, S; Morita, T; Nukui, A; Suzuki, K | 1 |
| Mazeron, JJ | 1 |
| Amin, MB; Bruner, DW; Chetner, MP; Hunt, D; Husain, SM; Jones, CU; Leibenhaut, MH; McGowan, DG; Rotman, M; Sandler, HM; Shipley, WU; Souhami, L | 1 |
| Both, S; Guzzo, TJ; Haas, NB; Hwang, WT; Jang, JW; Vapiwala, N; Wein, AJ | 1 |
| Chen, S; Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Jiang, PY; Kuo, KF; Pitzel, P; Yu, EY | 1 |
| Leitenberger, A; Loulidi, S; Mottet, N; Russel, C; Van Damme, J; Wolff, JM | 1 |
| Mazeron, JJ; Molinie, V; Mottet, N; Peneau, M; Richaud, P | 1 |
| Mearini, L | 1 |
| Jackson, M; Leong, E; Ng, E; Spry, N; Turner, S; Woo, HH | 1 |
| Goldenberg, SL; Ischia, J | 1 |
| Bolla, M | 1 |
| Baker, MK; England, PJ; Galvão, DA; Judge, JS; Newton, RU; Peddle-McIntyre, C; Spry, NA; Stephens, DA; Taaffe, DR | 1 |
| Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Hunter-Merrill, R; Kuo, KF; Yu, EY | 1 |
| Albertsson, P; Brandberg, Y; Damber, JE; Damm, O; Holmberg, E; Isacsson, U; Lennernäs, B; Ljung, G; Majumder, K; Nilsson, S | 1 |
| Amin, MB; Balogh, AG; Bauman, GS; Chinn, DM; Dignam, JJ; Duclos, M; Gomella, LG; Gore, EM; Hunt, D; Lukka, HR; Pisansky, TM; Rosenthal, SA; Rotman, MZ; Sandler, HM; Seider, MJ; Shipley, WU | 1 |
| Bahary, JP; Chafe, S; Efstathiou, JA; Gore, E; Husain, SM; Jones, CU; Leibenhaut, MH; McGowan, DG; Paulus, R; Raben, A; Rotman, M; Sandler, HM; Shipley, WU; Smith, MR; Souhami, L; Voog, JC; Zeitzer, KL | 1 |
| Scholz, MC; Strum, SB | 1 |
| Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X | 1 |
| García-Perdomo, HA; Reis, LO; Zani, EL | 1 |
| Cherrier, MM; Cross, DJ; Higano, CS; Minoshima, S | 1 |
| Dicker, AP; Gore, EM; Hartford, AC; Horwitz, EM; Hsu, IC; Jones, CU; Kim, HE; Kwok, Y; Lawton, CAF; Lee, WR; Michalski, JM; Moughan, J; Pisansky, TM; Pryzant, RM; Rabinovitch, R; Roach, M; Rotman, M; Sandler, HM; Seider, MJ; Shipley, WU; Thomas, CR; Yamoah, K; Zeitzer, KL | 1 |
| Bryant, AK; Deka, R; McKay, R; Murphy, JD; Nalawade, V; Rose, BS; Sarkar, RR; Simpson, DR | 1 |
15 review(s) available for flutamide and leuprolide
| Article | Year |
|---|---|
[Endometrioid adenocarcinoma of the prostate. Apropos of a case, review of the literature].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms | 1992 |
Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
Topics: Androgen Antagonists; Clinical Trials as Topic; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms | 1991 |
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Suramin; Survival Rate; Treatment Outcome | 1995 |
Role of induction androgen deprivation before radical prostatectomy.
Topics: Aged; Androgen Antagonists; Androgens; Clinical Trials as Topic; Flutamide; Humans; Leuprolide; Male; Prostatectomy; Prostatic Neoplasms | 1995 |
[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Hepatic Encephalopathy; Humans; Leuprolide; Male; Prostatic Neoplasms | 1996 |
[Total androgen blockade--concept, theory, method and clinical application].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms | 1998 |
Arguments for the long-term use of combined androgen blockade.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1998 |
Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Inappropriate ADH Syndrome; Leuprolide; Male; Paraneoplastic Endocrine Syndromes; Prostatic Neoplasms; Treatment Outcome; Vasopressins | 2000 |
Neoadjuvant hormone therapy: the Canadian trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Canada; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
[Total androgen blockade].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2002 |
Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Radiotherapy, Conformal | 2002 |
[Treatment of spinal and bulbar muscular atrophy].
Topics: Androgen Antagonists; Animals; Bulbar Palsy, Progressive; Flutamide; Humans; Leuprolide; Mice; Muscular Atrophy, Spinal; Peptides; Receptors, Androgen | 2004 |
Hormone ablation therapy: lightening the load for today's prostate cancer patient.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Monitoring; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Mass Screening; Neoplasm Staging; Nurse's Role; Nursing Assessment; Oligopeptides; Patient Education as Topic; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Treatment Outcome | 2007 |
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate | 2014 |
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Topics: Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2018 |
82 trial(s) available for flutamide and leuprolide
| Article | Year |
|---|---|
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbestrol; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Ketoconazole; Leuprolide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Remission Induction; Spironolactone; Survival Rate | 1992 |
Controversies in the treatment of metastatic prostate cancer.
Topics: Double-Blind Method; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate; United States | 1992 |
A pilot trial of chemohormonal therapy for metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Evaluation; Fluoxymesterone; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasms, Hormone-Dependent; Pilot Projects; Prostatic Neoplasms; Remission Induction; Survival Analysis | 1992 |
Luteinizing hormone releasing hormone agonists: the US experience.
Topics: Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic; United States | 1990 |
Leuprolide with and without flutamide in advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black People; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
Topics: Aged; Anilides; Antineoplastic Agents; Double-Blind Method; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Hormones; Humans; Leuprolide; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Evaluation; Flutamide; Gonadotropin-Releasing Hormone; Hormones; Humans; Leuprolide; Male; Prostatic Neoplasms; Survival Analysis; United States | 1990 |
Combination studies with leuprolide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Hormones; Humans; Leuprolide; Male; Prostatic Neoplasms; Survival Rate | 1990 |
Flutamide for prostate cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Neoplasm Metastasis; Prostatic Neoplasms | 1989 |
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1989 |
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1986 |
Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1993 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate; Tosyl Compounds; Treatment Failure | 1995 |
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Topics: Aged; Combined Modality Therapy; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Preoperative Care; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1995 |
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms | 1995 |
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms | 1993 |
Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Preoperative Care; Prostatectomy; Prostatic Neoplasms | 1993 |
Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Pilot Projects; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, High-Energy; Rectum; Urinary Bladder | 1994 |
Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Carcinoma in Situ; Case-Control Studies; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Orchiectomy; Prevalence; Prostatectomy; Prostatic Neoplasms | 1994 |
The use of flutamide in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Humans; Leuprolide; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Regression Analysis; Survival Rate | 1993 |
Total androgen blockade: the United States experience.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1993 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
[Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade].
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms | 1995 |
Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1996 |
Histopathological effects of androgen deprivation in prostatic cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Neoplasm Staging; Premedication; Prostatectomy; Prostatic Neoplasms | 1996 |
Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 1996 |
Combination treatment versus LHRH alone in advanced prostatic cancer.
Topics: Age Distribution; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1996 |
Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Prospective Studies; Prostatic Neoplasms | 1995 |
Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Flutamide; Humans; Leuprolide; Male; Neoplasm Invasiveness; Prognosis; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Single-Blind Method | 1994 |
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostatic Neoplasms | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms | 1997 |
Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms | 1997 |
PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Humans; Incidence; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1997 |
Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Diarrhea; Dose-Response Relationship, Drug; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms | 1996 |
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Survival Analysis; Treatment Outcome | 1997 |
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1997 |
Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Disease Progression; Drug Administration Schedule; Flutamide; Humans; Leuprolide; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 1998 |
Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fractionation, Radiation; Flutamide; Forecasting; Humans; Leuprolide; Lymph Node Excision; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Treatment Outcome | 1998 |
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1998 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Black People; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; White People | 1999 |
[Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostatic Neoplasms; Tegafur; Treatment Outcome; Uracil | 1999 |
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms | 1999 |
Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Cell Nucleus; Cohort Studies; Cytoplasm; Flutamide; Humans; Immunohistochemistry; Leuprolide; Male; Neoadjuvant Therapy; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Receptors, Androgen | 1999 |
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2000 |
[Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients].
Topics: Adrenocorticotropic Hormone; Aged; Androgens; Depression, Chemical; Diethylstilbestrol; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms | 2001 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2001 |
Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Time Factors | 2001 |
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2001 |
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report.
Topics: Adenoviridae; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Genetic Therapy; Genetic Vectors; Humans; Leuprolide; Lymphatic Irradiation; Male; Middle Aged; Prostatic Neoplasms; Simplexvirus; Thymidine Kinase | 2001 |
Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Drug Administration Schedule; Flutamide; Goserelin; Humans; Injections, Subcutaneous; Leuprolide; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms | 2001 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2002 |
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Longitudinal Studies; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Triptorelin Pamoate | 2002 |
Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Arteries; Cardiovascular Diseases; Flutamide; Goserelin; Hemodynamics; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Vascular Patency | 2002 |
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Attention; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Mental Recall; Middle Aged; Neoplasm Staging; Neuropsychological Tests; Problem Solving; Prostate-Specific Antigen; Prostatic Neoplasms; Space Perception; Testosterone | 2003 |
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Topics: Acyclovir; Adenoviridae; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antiviral Agents; Biopsy; Combined Modality Therapy; Flutamide; Follow-Up Studies; Genetic Therapy; Genetic Vectors; Humans; Leuprolide; Male; Middle Aged; Prodrugs; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Thymidine Kinase; Valacyclovir; Valine | 2004 |
Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Radiotherapy, Conformal | 2002 |
One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
Topics: Adult; Affect; Aged; Aged, 80 and over; Amyloid beta-Peptides; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Anxiety Disorders; Cognition; Depressive Disorder; Estradiol; Flutamide; Follow-Up Studies; Humans; Hypogonadism; Leuprolide; Male; Memory; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2004 |
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Adrenergic, alpha-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2004 |
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Drug Administration Schedule; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Testosterone; Treatment Failure | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Survival Analysis | 2004 |
Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Flutamide; Humans; Leuprolide; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Tamoxifen; Treatment Outcome | 2004 |
Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Administration Schedule; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Neoplasm Metastasis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Treatment Outcome | 2005 |
Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Flutamide; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Risk; Time Factors; Treatment Outcome | 2007 |
Early effects of pharmacological androgen deprivation in human prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2007 |
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Leuprolide; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2007 |
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors | 2008 |
Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Cohort Studies; Flutamide; Hip; Humans; Leuprolide; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Quality of Health Care; Spine; Testosterone; Time Factors | 2009 |
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Castration; Cause of Death; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality Therapy; Disease Progression; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Nitriles; Odds Ratio; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality Therapy; Drug Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Hematuria; Hemospermia; Humans; Incidence; Leuprolide; Logistic Models; Male; Middle Aged; Pain; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Surveys and Questionnaires | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Multivariate Analysis; Prostate; Prostatic Neoplasms; Radiotherapy; Radiotherapy Dosage; Risk; Survival Rate | 2011 |
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Diseases, Metabolic; Drug Administration Schedule; Flutamide; Fractures, Bone; Humans; Leuprolide; Linear Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Drug Administration Schedule; Flutamide; Humans; Kaplan-Meier Estimate; Leuprolide; Male; Prospective Studies; Prostatic Neoplasms; Tablets; Treatment Outcome | 2012 |
Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemoradiotherapy; Disease-Free Survival; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Prostate-Specific Antigen; Prostatic Neoplasms | 2012 |
The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Administration Schedule; Flutamide; Humans; Leuprolide; Libido; Male; Masculinity; Penile Erection; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Recovery of Function; Sexuality; Surveys and Questionnaires; Testosterone | 2012 |
Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Body Composition; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Time | 2013 |
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Testosterone; Time Factors; Treatment Outcome | 2015 |
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cost of Illness; Emotions; Erectile Dysfunction; Fecal Incontinence; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Social Participation; Surveys and Questionnaires; Survival Rate; Sweden; Urinary Incontinence | 2015 |
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Time Factors; Tosyl Compounds; Treatment Outcome | 2015 |
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Follow-Up Studies; Goserelin; Humans; Incidence; Leuprolide; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Time Factors | 2016 |
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Canada; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; Flutamide; Goserelin; Humans; Kallikreins; Leuprolide; Male; Neoplasm Grading; Neoplasm Staging; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; United States | 2018 |
98 other study(ies) available for flutamide and leuprolide
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.
Topics: Adult; Aged; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1992 |
[Complete androgenic blockade: myth or reality. Study and follow-up of 35 patients with advanced carcinoma of the prostate].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Retrospective Studies; Testosterone | 1992 |
Carcinoma of the prostate. Treating disease that has metastasized.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disseminated Intravascular Coagulation; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Pain; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Spinal Cord Compression | 1990 |
[The effects of antiprostatic agents on the accessory sex organs of rats treated with adrenal androgens].
Topics: Adrenal Glands; Androgen Antagonists; Androgens; Animals; Castration; Dihydrotestosterone; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Organ Size; Prostate; Rats; Rats, Inbred Strains; Testosterone | 1991 |
Maximal androgen blockade in prostatic cancer.
Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
Total androgen ablation: American experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1991 |
Pathologic changes associated with androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Immunoenzyme Techniques; Leuprolide; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms | 1991 |
Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer.
Topics: Anilides; Antineoplastic Agents; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Prostatic Neoplasms | 1990 |
Flutamide approved for prostate cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Hormone; Hormones; Humans; Leuprolide; Male; Prostatic Neoplasms | 1989 |
Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
Topics: Anilides; Animals; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Gonadotropin-Releasing Hormone; Imidazoles; Imidazolidines; Leuprolide; Male; Megestrol; Megestrol Acetate; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Receptors, Androgen | 1988 |
Hydroxyproline as a marker for following patients with metastatic prostate cancer.
Topics: Bone Neoplasms; Buserelin; Creatinine; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Hydroxyproline; Leuprolide; Male; Prostatic Neoplasms | 1988 |
Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
Topics: Adenocarcinoma; Adrenalectomy; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluation, Preclinical; Flutamide; Gonadotropin-Releasing Hormone; Leuprolide; Male; Neoplasm Transplantation; Orchiectomy; Prostatic Neoplasms; Rats; Rats, Inbred F344; Time Factors | 1988 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Megestrol; Megestrol Acetate; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1984 |
Adenocarcinoma of the prostate metastatic to the choroid of the eye.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Choroid Neoplasms; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms | 1995 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1995 |
Massive locally extensive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Constipation; Flutamide; Humans; Leuprolide; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage | 1994 |
Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Flutamide; Follow-Up Studies; Humans; Leuprolide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Time Factors | 1995 |
Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer.
Topics: Administration, Oral; Aged; Drug Therapy, Combination; Flutamide; Humans; Injections, Intramuscular; Leuprolide; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms | 1993 |
Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasms, Second Primary; Prostatic Neoplasms | 1995 |
Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Diethylstilbestrol; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms | 1994 |
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Creatinine; Flutamide; Humans; Hydrocortisone; Kidney; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Suramin | 1994 |
Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.
Topics: Cell Differentiation; Clinical Competence; Delphi Technique; Flutamide; Humans; Leuprolide; Luteinizing Hormone; Male; Pathology; Prostate; Prostatic Neoplasms | 1994 |
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Flutamide; Follow-Up Studies; Humans; Ketoconazole; Leuprolide; Male; Meningeal Neoplasms; Meningitis; Prostatic Neoplasms | 1994 |
Malignant pleural effusion from prostatic adenocarcinoma resolved with hormonal therapy.
Topics: Adenocarcinoma; Aged; Flutamide; Humans; Leuprolide; Male; Pleural Effusion, Malignant; Pleural Neoplasms; Prostatic Neoplasms | 1994 |
Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer.
Topics: Adrenal Glands; Androgen Antagonists; Androgens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Orchiectomy; Prostate; Prostatic Neoplasms | 1993 |
[Effects of androgen regulation system on bladder carcinogenesis in male mice].
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Butylhydroxybutylnitrosamine; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Leuprolide; Male; Mice; Mice, Inbred C3H; Orchiectomy; Urinary Bladder Neoplasms | 1995 |
Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Histiocytes; Histiocytosis; Humans; Leuprolide; Lymph Nodes; Lymphatic Diseases; Lymphatic Metastasis; Male; Pelvis; Prostatectomy; Prostatic Neoplasms; Xanthomatosis | 1996 |
Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms; Ursodeoxycholic Acid | 1996 |
Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Leuprolide; Luteinizing Hormone; Male; Organ Size; Pituitary Gland, Anterior; Prostate; Prostatic Neoplasms; Random Allocation; Rats; Seminal Vesicles; Testis; Testosterone | 1997 |
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma; Cholestenone 5 alpha-Reductase; Disease Models, Animal; Enzyme Inhibitors; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Immunohistochemistry; Leuprolide; Male; Mice; Mice, Inbred C3H; Oxidoreductases; Rats; Rats, Wistar; Urinary Bladder Neoplasms | 1997 |
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Biopsy; Disease Progression; Disease-Free Survival; Flutamide; Follow-Up Studies; Humans; Hydrocortisone; Leuprolide; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction | 1997 |
Correlation of testosterone with aggression in demented elderly men.
Topics: Age Factors; Aged; Aggression; Androgen Antagonists; Dementia; Flutamide; Humans; Leuprolide; Male; Psychiatric Status Rating Scales; Testosterone | 1997 |
Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Humans; Keratins; Leuprolide; Male; Neoplasm Proteins; Prognosis; Prostatectomy; Prostatic Neoplasms; Treatment Outcome; Ultrasonography | 1997 |
Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Hemoglobins; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Renal Dialysis | 1997 |
Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Flutamide; Humans; Immunoenzyme Techniques; In Situ Hybridization; Leuprolide; Male; Middle Aged; Neoplasm Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 1997 |
Acute renal failure in a patient receiving treatment with suramin.
Topics: Acute Kidney Injury; Adenocarcinoma; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Humans; Hydrocortisone; Leuprolide; Lumbar Vertebrae; Male; Middle Aged; Prostatic Neoplasms; Sacrum; Spinal Neoplasms; Suramin; Thoracic Vertebrae | 1997 |
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Diagnosis, Differential; Flutamide; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Pituitary Neoplasms; Prostatic Neoplasms; Time Factors | 1997 |
Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
Topics: Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Case-Control Studies; Combined Modality Therapy; Flutamide; Goserelin; Humans; Leuprolide; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 1997 |
Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Amyloidosis; Androgen Antagonists; Antineoplastic Agents, Hormonal; beta 2-Microglobulin; Biopsy; Drug Therapy, Combination; Epithelial Cells; Flutamide; Gonadotropin-Releasing Hormone; Humans; Immunoglobulin gamma-Chains; Immunoglobulin kappa-Chains; Immunohistochemistry; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Proteinuria; Seminal Vesicles; Serum Amyloid A Protein; Testicular Diseases | 1997 |
Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Female; Flutamide; Humans; Leuprolide; Male; Middle Aged; Myxoma; Ovary; Prostate; Prostatic Neoplasms | 1998 |
[Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Drug Administration Schedule; Flutamide; Leuprolide; Male; Organ Size; Prostatic Neoplasms; Rats | 1998 |
Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome; Ultrasonography, Interventional | 1998 |
Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Hot Flashes; Humans; Leuprolide; Male; Prostatectomy; Prostatic Neoplasms; Surveys and Questionnaires | 1998 |
Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Computer-Assisted; Retrospective Studies; Treatment Outcome | 1998 |
Successful treatment of stutter priapism with an antiandrogen.
Topics: Adult; Androgen Antagonists; Anemia, Sickle Cell; Flutamide; Gynecomastia; Headache; Humans; Leuprolide; Male; Mastectomy; Priapism; Radiotherapy; Treatment Outcome | 1998 |
Interstitial pneumonitis related to leuprorelin acetate and flutamide.
Topics: Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Lung Diseases, Interstitial; Male; Prostatic Neoplasms | 1999 |
Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy.
Topics: Antineoplastic Agents, Hormonal; Chromogranin A; Chromogranins; Flutamide; Humans; Immunoenzyme Techniques; Leuprolide; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 1999 |
A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Disease Progression; Drug Administration Schedule; Flutamide; Follow-Up Studies; Fractures, Bone; Goserelin; Humans; Leuprolide; Lumbar Vertebrae; Male; Middle Aged; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Survival Rate; Testosterone; Treatment Outcome | 2000 |
Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Health Status Indicators; Humans; Leuprolide; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Quality of Life; Stress, Psychological | 2000 |
[Changes in liver function induced by flutamide in patients with prostate cancer (studies in patients treated with total androgen blockage)].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Cholinesterases; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prostatic Neoplasms | 2000 |
Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Ultrasonography | 2000 |
Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Humans; Leuprolide; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Prostatectomy; Prostatic Neoplasms; Recurrence; Treatment Outcome | 2000 |
Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoembryonic Antigen; Flutamide; Humans; Immunohistochemistry; Keratins; Leuprolide; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Sarcoma | 2000 |
Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Flutamide; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prostate; Prostatic Neoplasms; Treatment Outcome; Ultrasonography | 2000 |
Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Neoplasm, Residual; Nitriles; Prostate; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2000 |
Chemical andropause and amyloid-beta peptide.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Androgen Antagonists; Antineoplastic Agents, Hormonal; Estradiol; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Testosterone | 2001 |
[Anemia and neoadjuvant hormone therapy in radical surgery of localized cancer of the prostate].
Topics: Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Hematocrit; Hemoglobins; Humans; Leuprolide; Male; Prostatic Neoplasms; Triptorelin Pamoate | 2001 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2001 |
[The effect of combined endocrine therapy on prostate and testis].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Atrophy; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostate; Prostatic Neoplasms; Testis | 1999 |
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Body Composition; Body Mass Index; Bone Density; Bone Diseases, Metabolic; Flutamide; Hip Joint; Humans; Leuprolide; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Thinness | 2002 |
Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2002 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers; Bone Density; Bone Remodeling; Calcium; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2002 |
Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dose-Response Relationship, Radiation; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Observer Variation; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Rectum; Treatment Outcome | 2003 |
Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy.
Topics: Androgen Antagonists; Animals; Disease Models, Animal; Female; Flutamide; Humans; Leuprolide; Male; Mice; Mice, Transgenic; Motor Activity; Muscle, Skeletal; Muscular Disorders, Atrophic; Organ Size; Peptides; Phenotype; Receptors, Androgen; Spinal Cord; Testosterone | 2003 |
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Flutamide; Humans; Leuprolide; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Orchiectomy; Postoperative Complications; Prostatic Neoplasms; Radiography; Testicular Neoplasms | 2003 |
Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Matched-Pair Analysis; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2004 |
Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Bilirubin; Biomarkers, Tumor; Cholangiopancreatography, Endoscopic Retrograde; Diagnosis, Differential; Flutamide; gamma-Glutamyltransferase; Humans; Jaundice, Obstructive; Leuprolide; Male; Paraneoplastic Syndromes; Prostatic Neoplasms; Pruritus; Tomography, X-Ray Computed; Transaminases | 2003 |
Biochemical remission after resection of prostate cancer lung metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; Cough; Disease-Free Survival; Dyspnea; Flutamide; Follow-Up Studies; Humans; Leuprolide; Lung Neoplasms; Male; Neoplasm Proteins; Pneumonectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Remission Induction | 2004 |
Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cognition; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Neuropsychological Tests; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2004 |
Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 2004 |
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studies; Flutamide; Gastrointestinal Tract; Goserelin; Hormones; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Regression Analysis; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome; Urogenital System | 2005 |
Coagulopathy, following medical therapy, for carcinoma of the prostate.
Topics: Aged; Blood Coagulation Disorders; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Fibrinolysis; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms | 2005 |
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Leuprolide; Male; Male Urogenital Diseases; Nitriles; Prostatic Neoplasms; Radiation Injuries; Time Factors; Tosyl Compounds | 2005 |
Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Leuprolide; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Testosterone | 2006 |
The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Japan; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds | 2006 |
[Histological investigation of prostate cancer treated with hormonal agents].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Keratins; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostate; Prostatic Neoplasms | 2006 |
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Needle; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endosonography; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2007 |
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Biomarkers, Tumor; Dihydrotestosterone; Disease Progression; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Orchiectomy; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2007 |
Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Fatal Outcome; Flutamide; Humans; Leuprolide; Liver Neoplasms; Male; Prostatic Neoplasms; Tumor Lysis Syndrome | 2007 |
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions; Flutamide; Humans; Imidazolidines; Leuprolide; Male; Patient Education as Topic; Patient Satisfaction; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis | 2008 |
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Nitriles; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Tosyl Compounds; Treatment Failure | 2009 |
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Cyproterone; Flutamide; Humans; Killer Cells, Natural; Leuprolide; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; T-Lymphocytes | 2009 |
Addressing bone loss in the cancer survivor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Female; Flutamide; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Neoplasms; Osteoporosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Survivors | 2009 |
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Japan; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2011 |
[Hormone therapy of locally advanced cancer of the prostate validated by several randomized trials].
Topics: Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Reproducibility of Results | 2011 |
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Seminal Vesicles; Tosyl Compounds | 2012 |
Editorial comment.
Topics: Androgen Antagonists; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms; Sexuality; Testosterone | 2012 |
Intermittent androgen suppression--ready for prime time?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms; Sexuality; Testosterone | 2012 |
The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approach.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms | 2012 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
Topics: Androgen Antagonists; Androgens; Anilides; Drug-Related Side Effects and Adverse Reactions; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Libido; Male; Medicare; Neoplasm Metastasis; Nitriles; Penis; Prostatic Neoplasms; Tosyl Compounds; United States | 2016 |
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; California; Cardiovascular Diseases; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Heart Failure; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Nitriles; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tosyl Compounds | 2017 |
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.
Topics: Affect; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Brain; Cognition; Flutamide; Humans; Kallikreins; Leuprolide; Male; Middle Aged; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life | 2018 |
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Depressive Disorder; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hospitalization; Humans; Imidazolidines; Leuprolide; Male; Mental Health Services; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Suicide; Tosyl Compounds | 2019 |